|(1S,2S,3R,4S,5S)-5-((1,3-二羟丙基-2-基)氨基)-1-(羟甲基)环己烷-1,2,3,4-四醇|CsnPharm

CAS No.: 83480-29-9

Voglibose/伏格列波糖 Catalog No. CSN12212

Synonyms: AO 128;Glustat;Vocarb

Voglibose, an N-substituted derivative of valiolamine, can inhibit α-glucosidase and be used to treat hyperglycemia and its concomitant diseases.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述D-Glucose and insulin levels of plasma are usually high in diabetics especially after food ingestion, and reducing intestinal carbohydrate absorption, such as monosaccharides, which are hydrolyzed by α-glucosidase, is one way to control disorders of carbohydrate metabolism. Voglibose, a α-glucosidase inhibitor, delays the digestion and absorption of carbohydrates and is the aid in the treatment of diabetes^[3]. In the case of postprandial glucose excursion, oral administration of voglibose (0.2 mg/kg) reduced the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats^[4]. In prediabetic db/db mice, voglibose decreased the average food consumption by 37% compared with vehicle-treated mice. Furthermore, voglibose treatment increased GLP-1 (glucagon-like peptide-1) secretion, while it decreased plasma glucose-dependent insulinotropic polypeptide (GIP)^[5].
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02456428	-	-	Completed	-	Canada, Quebec ... more >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Collapse <<
NCT02476760	-	-	Completed	-	Canada, Quebec ... more >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Collapse <<
NCT02685410	HIV Prevention ... more >> STI Prevention Collapse <<	Not Applicable	Completed	-	United States, Connecticut ... more >> Yale New Haven Hospital New haven, Connecticut, United States, 06510 Collapse <<

更多
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 3.7414 mL
- 18.7072 mL
- 37.4145 mL
- 5 mM
- 0.7483 mL
- 3.7414 mL
- 7.4829 mL
- 10 mM
- 0.3741 mL
- 1.8707 mL
- 3.7414 mL

技术信息

CAS号

83480-29-9

储存条件

粉末: Keep in dark place,Sealed in dry,Store in freezer, under -20°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C10H21NO7

运输

蓝冰

分子量

267.28

别名

AO 128;Glustat;Vocarb;Basen;Basen OD;Voglib;伏格列波糖

溶解度

DMSO	74.0 mg/mL (276.9 mM)
Ethanol	Insoluble

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02456428	-	-	Completed	-	Canada, Quebec ... more >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Collapse <<
NCT02476760	-	-	Completed	-	Canada, Quebec ... more >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Collapse <<
NCT02685410	HIV Prevention ... more >> STI Prevention Collapse <<	Not Applicable	Completed	-	United States, Connecticut ... more >> Yale New Haven Hospital New haven, Connecticut, United States, 06510 Collapse <<
NCT03157895	Relationship, Family (Foster) ... more >> Substance Use Prevention Collapse <<	Not Applicable	Recruiting	January 31, 2020	United States, Washington ... more >> Social Development Research Group Recruiting Seattle, Washington, United States, 98115 Contact: Jessica Colito, MSW 206-221-5250 jcolito@uw.edu Contact: Patricia Gomez 206-616-7931 pagomez@uw.edu Principal Investigator: Kevin Haggerty, PhD Sub-Investigator: Susan Barkan, PhD Collapse <<
NCT02475499	-	-	Completed	-	Canada, Quebec ... more >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Collapse <<
NCT00985400	Colorectal Cancer	Not Applicable	Active, not recruiting	November 2020	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030-4009 Collapse <<
NCT00454766	-	-	Active, not recruiting	February 2019	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT00853203	-	-	Active, not recruiting	January 2019	United States, Texas ... more >> Kelsey-Seybold Clinics Houston, Texas, United States, 77030 University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT01504919	Psychosocial Problem	Not Applicable	Active, not recruiting	January 2019	United States, Texas ... more >> William Marsh Rice University Houston, Texas, United States, 77005 University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT01311856	-	-	Active, not recruiting	March 2020	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT00473798	-	-	Active, not recruiting	July 2020	United States, Texas ... more >> Hermann Professional Building Clinic Houston, Texas, United States, 77030 LBJ Hospital Houston, Texas, United States, 77030 Texas Medical Center Clinic Houston, Texas, United States, 77030 University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Canada, British Columbia Vancouver General Hospital/British Columbia Cancer Agency Vancouver, British Columbia, Canada, V5Z 1M9 Collapse <<
NCT00533338	Breast Cancer	Not Applicable	Active, not recruiting	July 2019	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT01504789	Breast Cancer	Not Applicable	Active, not recruiting	February 2019	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Puerto Rico University of Puerto Rico San Juan, Puerto Rico, 00936 Collapse <<
NCT02774759	Malignant Neoplasms of Female ... more >>Genital Organs Collapse <<	Not Applicable	Active, not recruiting	October 2020	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT00633633	Heart Failure	Not Applicable	Active, not recruiting	February 2021	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 The University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78249 Collapse <<
NCT01697592	Type 2 Diabetes Mellitus	Phase 3	Completed	-	-
NCT00501761	-	-	Active, not recruiting	May 2019	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT01646788	Obstructive Lesions of Arterio... more >>venous Dialysis Fistulae Collapse <<	Not Applicable	Unknown	January 2015	Israel ... more >> The Rabin Medical Center, Hasharon Hospital Not yet recruiting Petah Tikva, Israel Collapse <<
NCT00542438	Cardiovascular Disease	Not Applicable	Active, not recruiting	October 2019	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT02593422	Ovarian Cancer	Not Applicable	Completed	-	United States, Maryland ... more >> University of Maryland, College Park College Park, Maryland, United States, 20742 Collapse <<
NCT02194387	Breast Cancer ... more >> Ovarian Cancer Collapse <<	Not Applicable	Recruiting	September 2019	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Collapse <<
NCT01682824	-	-	Active, not recruiting	May 31, 2019	United States, Texas ... more >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Collapse <<
NCT01242202	Type 2 Diabetes Mellitus	Phase 3	Completed	-	Japan ... more >> Chubu, Japan Hokkaido, Japan Kansai, Japan Kantou, Japan Kyushu, Japan Touhoku, Japan Collapse <<
NCT01263470	-	-	Completed	-	-
NCT01697592	-	-	Completed	-	-
NCT02287402	Impaired Glucose Tolerance (IG... more >>T) Collapse <<	Phase 4	Completed	-	-
NCT01263470	Diabetes Mellitus, Type 2	Phase 2	Completed	-	Japan ... more >> Okayama, Japan, 701-0192 Collapse <<
NCT02287402	-	-	Completed	-	-
NCT00724542	Coronary Heart Disease ... more >> Impaired Glucose Tolerance Collapse <<	Not Applicable	Unknown	December 2010	China, Beijing ... more >> Peking University First Hospital Recruiting Beijing, Beijing, China, 100034 Contact: Wenhui Ding, Professor 86-10-66551122 ext 5001 dwh_rd@126.com Collapse <<
NCT01263496	Type 2 Diabetes Mellitus	Phase 2	Completed	-	-
NCT02097342	Type 2 Diabetes Mellitus ... more >> Insulin Sensitivity/Resistance Collapse <<	Phase 4	Unknown	January 2015	India ... more >> Postgraduate Institute of Medical Education & Research Recruiting Chandigarh, India, 160012 Contact: Anil Bhansali, MD DM anilbhansaliendocrine@gmail.com Collapse <<
NCT00970528	Diabetes Mellitus, Type 2	Phase 4	Completed	-	Korea, Republic of ... more >> Wonju-si, Gang''weondo, Korea, Republic of, 220-701 Busan, Korea, Korea, Republic of, 602-714 Gyeonggi-do, Korea, Korea, Republic of, 463-500 Gyeonggi-do, Korea, Korea, Republic of, 471-701 Pusan, Korea, Korea, Republic of, 602-739 Seoul, Korea, Korea, Republic of, 150-713 Daegu, Korea, Republic of, 705-717 Jeonju-si, Korea, Republic of, 456-712 Seongbuk-gu Seoul, Korea, Republic of, 136-705 Seoul, Korea, Republic of, 134-701 Seoul, Korea, Republic of, 135-710 Collapse <<
NCT01263496	-	-	Completed	-	-
NCT00212017	Impaired Glucose Tolerance ... more >> Myocardial Infarction Collapse <<	Not Applicable	Terminated(We obtained the fin... more >>al results due to the interim analysis.) Collapse <<	-	Japan ... more >> National Cardiovascular Center Suita, Osaka, Japan, 565-8565 Collapse <<
NCT03546972	Obesity and Other Hyperaliment... more >>ation Collapse <<	Not Applicable	Recruiting	November 2019	United States, Texas ... more >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact kbasenen@mdanderson.org Collapse <<
NCT01263483	Type 2 Diabetes Mellitus	Phase 2 Phase 3	Completed	-	-
NCT01263509	Type 2 Diabetes Mellitus	Phase 2 Phase 3	Completed	-	-
NCT01263483	-	-	Completed	-	-
NCT00411554	Diabetes Mellitus, Non-Insulin... more >>-Dependent Collapse <<	Phase 3	Completed	-	-
NCT01263509	-	-	Completed	-	-
NCT00411554	-	-	Completed	-	-
NCT00654381	Diabetes Mellitus, Type 2	Phase 3	Completed	-	Japan ... more >> 1218.23.05 Boehringer Ingelheim Investigational Site Asahi, Chiba, Japan 1218.23.06 Boehringer Ingelheim Investigational Site Funabashi, Chiba, Japan 1218.23.21 Boehringer Ingelheim Investigational Site Hitachinaka, Ibaraki, Japan 1218.23.44 Boehringer Ingelheim Investigational Site Hitachiota, Ibaraki, Japan 1218.23.09 Boehringer Ingelheim Investigational Site Imizu, Toyama, Japan 1218.23.45 Boehringer Ingelheim Investigational Site Inashiki-gun, Ibaraki, Japan 1218.23.13 Boehringer Ingelheim Investigational Site Izumisano, Osaka, Japan 1218.23.27 Boehringer Ingelheim Investigational Site Kariya, Aichi, Japan 1218.23.47 Boehringer Ingelheim Investigational Site Kitakatsushika-gun, Saitama, Japan 1218.23.39 Boehringer Ingelheim Investigational Site Kitakyuushuu, Fukuoka, Japan 1218.23.02 Boehringer Ingelheim Investigational Site Koriyama, Fukushima, Japan 1218.23.03 Boehringer Ingelheim Investigational Site Koriyama, Fukushima, Japan 1218.23.10 Boehringer Ingelheim Investigational Site Kyoto, Kyoto, Japan 1218.23.37 Boehringer Ingelheim Investigational Site Marugame, Kagawa, Japan 1218.23.38 Boehringer Ingelheim Investigational Site Marugame, Kagawa, Japan 1218.23.23 Boehringer Ingelheim Investigational Site Matsumoto, Nagano, Japan 1218.23.07 Boehringer Ingelheim Investigational Site Meguro-ku, Tokyo, Japan 1218.23.25 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.26 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.28 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.29 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.30 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1218.23.04 Boehringer Ingelheim Investigational Site Naka, Ibaraki, Japan 1218.23.15 Boehringer Ingelheim Investigational Site Nishi-ku, Hiroshima, Hiroshima, Japan 1218.23.34 Boehringer Ingelheim Investigational Site Nishi-ku, Sakai, Osaka, Japan 1218.23.22 Boehringer Ingelheim Investigational Site Nishishinjyuku, Shinjyuku-ku, Tokyo, Japan 1218.23.16 Boehringer Ingelheim Investigational Site Oita, Oita, Japan 1218.23.40 Boehringer Ingelheim Investigational Site Oita, Oita, Japan 1218.23.36 Boehringer Ingelheim Investigational Site Okayama, Okayama, Japan 1218.23.11 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.12 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.32 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.33 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.35 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1218.23.17 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.18 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.19 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.41 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.42 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.43 Boehringer Ingelheim Investigational Site Sapporo, Hokkaido, Japan 1218.23.01 Boehringer Ingelheim Investigational Site Sendai, Miyagi, Japan 1218.23.20 Boehringer Ingelheim Investigational Site Sendai, Miyagi, Japan 1218.23.46 Boehringer Ingelheim Investigational Site Shinjuku-ku, Tokyo, Japan 1218.23.08 Boehringer Ingelheim Investigational Site Shinjyuku-ku,Tokyo, Japan 1218.23.14 Boehringer Ingelheim Investigational Site Suita, Osaka, Japan 1218.23.31 Boehringer Ingelheim Investigational Site Takatsuki, Osaka, Japan 1218.23.48 Boehringer Ingelheim Investigational Site Yokohama, Kanagawa, Japan Collapse <<
NCT00837577	-	-	Completed	-	-
NCT01309698	Type 2 Diabetes	Phase 4	Completed	-	Japan ... more >> Novartis Investigative Site Tokyo, Japan Collapse <<
NCT00654381	-	-	Completed	-	-
NCT00368134	Diabetes Mellitus, Type 2	Phase 3	Completed	-	Japan ... more >> Novartis Pharmaceuticals Tokyo, Japan Collapse <<
NCT01055652	Type 2 Diabetes Mellitus	Phase 1	Completed	-	Japan ... more >> Research Site Moriya, Japan Research Site Osaka, Japan Collapse <<
NCT02049814	Type 2 Diabetes Mellitus	Phase 4	Completed	-	China, Anhui ... more >> Hefei, Anhui, China Maanshan, Anhui, China China, Beijing Beijing, Beijing, China China, Guangdong Guangzhou, Guangdong, China Shenzhen, Guangdong, China Taishan, Guangdong, China China, Hunan Zhuzhou, Hunan, China China, Jiangsu Nanjing, Jiangsu, China Xuzhou, Jiangsu, China China, Jilin Changchun, Jilin, China Jilin, Jilin, China China, Liaoning Shenyang, Liaoning, China China, Shandong Qingdao, Shandong, China China, Shanghai Shanghai, Shanghai, China China, Shanxi Yan An, Shanxi, China Yanan, Shanxi, China China, Tianjin Tianjin, Tianjin, China China, Zhejiang Wenzhou, Zhejiang, China Collapse <<
NCT01993927	-	-	Completed	-	Japan ... more >> Osaka, Japan Collapse <<
NCT01993927	-	-	Completed	-	-
NCT00663884	Diabetes Mellitus, Type 2	Phase 4	Completed	-	Korea, Republic of ... more >> The Catholic Univ. of Korea, Kangnam ST. Mary's Hospital Seoul, Korea, Republic of, 137-701 Collapse <<
NCT00837577	Diabetes Mellitus, Non-Insulin... more >>-Dependent Collapse <<	Phase 3	Completed	-	-

Voglibose/伏格列波糖 Catalog No. CSN12212

靶点选择性

请登录您的专属账户

确认信息